Holen Sie sich die Stockscreener-App
1.59
1.85%
-0.03
Handel nachbörslich:
1.55
-0.04
-2.52%
Schlusskurs vom Vortag:
$1.62
Offen:
$1.66
24-Stunden-Volumen:
19,077
Relative Volume:
0.03
Marktkapitalisierung:
$3.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.69M
KGV:
-0.4297
EPS:
-3.7
Netto-Cashflow:
$-3.81M
1W Leistung:
-3.64%
1M Leistung:
-15.87%
6M Leistung:
-35.38%
1J Leistung:
-47.00%
1-Tages-Spanne:
$1.51
$1.66
1-Wochen-Bereich:
$1.51
$1.76
52-Wochen-Spanne:
$1.31
$4.42
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Firmenname
Lixte Biotechnology Holdings Inc
Sektor
Branche
Telefon
310 203 2902
Adresse
248 ROUTE 25A, EAST SETAUKET
Vergleichen Sie LIXT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| LIXT | 1.59 | 3.62M | 0 | -4.69M | -3.81M | -3.70 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Lixte Biotechnology Holdings Inc Aktie (LIXT) Neueste Nachrichten
LIXTW (Lixte Biotechnology Holdings) Accounts Payable & Acc - GuruFocus.com
LIXT stock touches 52-week low at $1.53 amid market challenges - Investing.com Australia
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
LIXT stock touches 52-week low at $1.53 amid market challenges By Investing.com - Investing.com South Africa
Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com Australia
Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com
Lixte Biotechnology Holdings Inc WT (LIXTW-Q) QuotePress Release - The Globe and Mail
Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com
MRVI Stock Drops 5.11% Amid Financial Report Release - GuruFocus.com
Lixte Biotechnology (NASDAQ:LIXT) Stock Price Down 2.1% - Defense World
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy - GlobeNewswire
Should investors be concerned about LYT’s high price-to-sales ratio? - US Post News
Lilium (NASDAQ:LILM) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Liquidia Co. (NASDAQ:LQDA) Shares Bought by Rhumbline Advisers - Defense World
Pacer Advisors Inc. Has $16.07 Million Stock Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World
Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex
Renaissance Technologies LLC Sells 2,000 Shares of LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Texas Permanent School Fund Corp Trims Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World
First Eagle Investment Management LLC Increases Stake in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Huber Capital Management LLC Acquires 241,814 Shares of Lyft, Inc. (NASDAQ:LYFT) - Defense World
Acadian Asset Management LLC Cuts Position in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Quest Partners LLC Invests $28,000 in LSI Industries Inc. (NASDAQ:LYTS) - Defense World
Investors who lost money with shares of Liquidia Corporation - openPR
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia CorporationLQDA - Kilgore News Herald
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Biotech Steals The Show Following Pre-Clinical Data Announcement - MSN
Lixte Biotechnology Holdings Inc (LIXT) Stock: A Year of Decreases and Increases - The InvestChronicle
LIXTLixte Biotechnology Holdings, Inc. Latest Stock News & Market Updates - StockTitan
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology - GlobeNewswire
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World
Why Nordstrom Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Market Recap Check: Lixte Biotechnology Holdings Inc (LIXT)’s Positive Finish at 2.00, Up/Down 11.12 - The Dwinnex
LIXT Stock: A Voyage Through Lixte Biotechnology Holdings Inc’s Finances - The InvestChronicle
LIXT stock touches 52-week low at $1.55 amid market fluctuations - Investing.com
First Patient Dosed with LIXTE’s LB-100 in New Clinical - GlobeNewswire
First Patient Dosed with Lixte Biotechnology Holdings, Inc.?s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - Marketscreener.com
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - StockTitan
Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India
LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 20, 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) PS Ratio : (As of Aug. 19, 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXTE Biotechnology Provides Update On Recent Activities and Developments - ForexTV.com
LIXT (Lixte Biotechnology Holdings) Purchase Of Investment : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Owner Earnings per Shar - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Debt-to-Equity : 0.00 (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Effective Interest Rate on Debt % : 0.00% (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Float Percentage Of Tot - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Interest Coverage : 0 (At Loss) (As of Jun. 2024) - GuruFocus.com
LIXT (Lixte Biotechnology Holdings) Capex-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
Finanzdaten der Lixte Biotechnology Holdings Inc-Aktie (LIXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):